Key information for investors | Gentian Diagnostics AS
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
15612
page-template,page-template-full_width,page-template-full_width-php,page,page-id-15612,page-child,parent-pageid-15340,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Key information

Key information

Gentian Diagnostics AS serves the global market with sensitive diagnostic tests. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.

 

On 14th December, 2016, Gentian Diagnostics AS was admitted to the Oslo Stock Exchange list ‘Merkur Market’ under the ticker GENT-ME.

 

Find more information about the Gentian Share on Oslo Børs.

 

Learn more about Gentian Diagnostics AS here.

EXTRAORDINARY GENERAL MEETING
GENTIAN DIAGNOSTICS AS 21/11/2019

The extraordinary general meeting of Gentian Diagnostics AS will be held at the Company’s
offices in: Bjørnåsveien 5, 1596 Moss, 21 November 2019 at 10:00 CET

 

For more information, please see the documents below:

 

28th of May 2019: Annual General Meeting

Annual General Meeting for Gentian Diagnostics AS was hold on the 28th of May 2019.

For more information, please see the notice and documents below:

Presentations

Historical

Look at our historical archive to find financial reports and data from 2018, 2017 and 2016.